Accessibility Menu
Tivic Health Systems logo

Tivic Health Systems

(NASDAQ) VBIO

Current PriceN/A
Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 YearN/A
1 Year-88%
1 Month-19%
Tivic Health Systems last closing stock price
MetricPriceDate
Last closeUSD 0.452026-07-15
Tivic Health Systems stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.96%USD 0.492026-07-08
1 month-19.32%USD 0.562026-06-15
3 month-60.09%USD 1.132026-04-16
Year to date-68.9%USD 1.452025-12-31
1 year-88.47%USD 3.912025-07-15
3 year-99.58%USD 107.612023-07-14
Since inception-99.99%USD 8,823.002021-11-11

Tivic Health Systems Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.69M

Net Income (TTM)

-$3.58M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 17, 2026

VBIO News

Foolcom-Featured.png

Tivic Health Sales Drop 39 Percent

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tivic Health Systems

Tivic Health makes devices and medicines for people with sinus and immune problems. Its main product, ClearUP, helps relieve sinus pain without drugs. The company also develops new treatments for serious immune conditions.

Gadgets and Goodies: Tivic’s Main Offerings

  • ClearUP Device: Handheld, non-invasive device for sinus pain and congestion relief; currently generates all product revenue.
  • ncVNS System: Non-invasive nerve stimulation device in clinical research; aims to treat neurological and heart-related conditions.
  • Entolimod (Biopharma): Late-stage drug candidate for acute radiation syndrome and immune disorders; licensed in 2025.
  • Entolasta (Biopharma): Second-generation immune therapy; exclusive option rights for future use.

Plot Twists: Tivic’s Growth Moves

  • Acquired exclusive worldwide license to Entolimod from Statera Biopharma for the ARS indication in 2025 and obtained an exclusive option for additional indications.
  • Signed manufacturing deal with Scorpius BioManufacturing for Entolimod in 2025.
  • Partnered with The Feinstein Institutes for Medical Research for nerve stimulation studies in 2025.
  • Launched Series B Preferred Stock financing and equity line with Mast Hill Fund in 2025.

What Makes Tivic Tick

Tivic combines medical devices and drug development under one roof. It sells directly to consumers and through major online retailers. The company uses partnerships to keep operations lean and flexible.

Five Things You Need to Know

  • Q2 2025 revenue was $86,000, down 38.6% from Q2 2024.
  • All revenue in 2025 came from ClearUP device sales in the U.S.
  • Q2 2025 net loss was $1.93 million, a 52.5% larger loss compared to Q2 2024.
  • Operating expenses rose to $1.99 million in Q2 2025, compared to $1.30 million in Q2 2024.
  • Cash and equivalents were $1.18 million as of June 30, 2025.

Bottom Line

Tivic has shifted from a single-device focus to a mix of devices and drug development. The company faces financial challenges but continues to diversify its healthcare offerings.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

9

CEO

Michael Kevin Handley, EMBA

Website

www.tivichealth.com

Headquarters

San Antonio, TX 78205, US

VBIO Financials

Key Financial Metrics (TTM)

Gross Margin

-11.32%

Operating Margin

-141.91%

Net Income Margin

-145.62%

Return on Equity

-18.83%

Return on Capital

-270.82%

Return on Assets

-2.06%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$191.73K

Operating Income

-$3.52M

EBITDA

-$166.63K

Operating Cash Flow

-$962.94K

Capital Expenditure

$0.00

Free Cash Flow

-$962.94K

Cash & ST Invst.

$1.28M

Total Debt

$500.00K

Tivic Health Systems Performance Analysis

Tivic Health Systems annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,840,00046.4%
20232023-12-31USD 1,176,000-36.1%
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Tivic Health Systems sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12021-06-30N/A
Q22021-09-30N/A
Q22025-09-30N/A
Q42026-03-31N/A
Tivic Health Systems annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1,773.46-57.1%
20232023-12-31USD -176.72-90.0%
20242024-12-31USD -19.68-88.9%
20252025-12-31USD -7.58-61.5%
Tivic Health Systems sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12021-06-30-70.4%
Q22021-09-3018.2%
Q22025-09-30N/A
Q42026-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$915.38K

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

52

N/A

Net Income

-$1.83M

-408.5%

EBITDA

$799.58K

+321.7%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$1.28M

+45.1%

Total Debt

$500.00K

N/A

Accounts Receivable

$950.11K

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$500.00K

N/A

Return on Assets

-2.06%

N/A

Return on Invested Capital

-2.08%

N/A

Free Cash Flow

-$982.05K

-76.2%

Operating Cash Flow

-$982.05K

-76.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OCELOrganicell Regenerative Medicine, Inc.
$2.74-0.27%
AMHVAmerican Hemp Ventures, Inc.
$0.98+0.00%
ATHJFAntisense Therapeutics Limited
$0.01-76.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$15.60-0.00%
NUNu Holdings
$13.79-0.01%
ATAIAtaiBeckley
$7.15+0.33%
NOKNokia
$10.38-0.08%

Questions About VBIO

What is the current price of Tivic Health Systems?

Tivic Health Systems is trading at N/A per share.

What is the 52-week range for Tivic Health Systems?

Over the past 52 weeks, Tivic Health Systems has traded between N/A and N/A.

How much debt does Tivic Health Systems have?

As of the most recent reporting period, Tivic Health Systems reported total debt of $17.03M.

How much cash does Tivic Health Systems have on hand?

Tivic Health Systems reported $7.22M in cash and cash equivalents in its most recent financial results.

What is Tivic Health Systems’s dividend yield?

Tivic Health Systems does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services